| 特征 | 分组 | 例数 | 进展率 | P值 | 中位PFS (95%CI) | P值 |
| N分期 |
|
|
| 0.002 |
| 0.002 |
|
| N1期 | 8 | 25.0% |
| 50 (21~78) |
|
|
| N2期 | 9 | 100.0% |
| 21 (5~37) |
|
| M分期 |
|
|
| 0.290 |
| 0.055 |
|
| M0期 | 10 | 50.0% |
| 32 (27~37) |
|
|
| M1a期 | 4 | 75.0% |
| 21 (9~33) |
|
|
| M1b期 | 4 | 100.0% |
| 6 |
|
| TNM分期 |
|
|
| 0.009 |
| 0.008 |
|
| IVA期 | 9 | 33.3% |
| 50 (21~79) |
|
|
| IVB期 | 9 | 100.0% |
| 21 (5~37) |
|
| 治疗模式 |
|
|
| 0.793 |
| 0.057 |
|
| 单纯化疗 | 8 | 75.0% |
| 24 (16~32) |
|
|
| 放化疗 | 6 | 50.0% |
| 50 (27~73) |
|
|
| 化疗联合免疫疗法 | 3 | 66.7% |
| 10 (4~16) |
|
| 治疗效果 |
|
|
| 0.638 |
| 0.147 |
|
| PR | 10 | 60.0% |
| 30 (24~36) |
|
|
| SD | 8 | 75.0% |
| 21 (5~37) |
|